Plasma levels of soluble receptor for advanced glycation end products in Alzheimer's disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A decreased plasma level of soluble form of the receptor for advanced glycation end products (sRAGE) in patients with Alzheimer's disease (AD) has been reported. However, no evidence has shown whether the sRAGE plasma level of AD patients may differentiate from other types of dementia. METHODS: Our study assessed sRAGE concentrations in the following 121 individuals in Chongqing area: 36 patients with AD, 12 with vascular dementia (VaD), 14 with mixed dementia (MD), 24 with other dementia (OD) including Parkinson's disease dementia, frontotemporal dementia, paralytic dementia and 35 cognitively normal controls. The total plasma level of sRAGE was determined using sandwich ELISA method. RESULTS: sRAGE concentration in AD is significantly decreased compared with healthy controls. However, the receiver operating characteristic curve analysis of sRAGE between the AD and the control shows a low diagnostic accuracy. CONCLUSIONS: Our results demonstrate that sRAGE may assist the diagnosis of AD from normal individuals, but cannot differentiate AD from VaD, MD or OD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Role of advanced glycation end products in cellular signaling
Ott, C., Jacobs, K., Haucke, E., Navarrete Santos, A., Grune, T., & Simm, A. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.016 · Cited by 1,150 · cited 1×
“AGE-RAGE axis may alter several cell functions through modulation of multiple intracellular signaling pathways, resulting in the transcription of target genes and generation of oxidative stress [7,8].”
BackgroundAdvanced glycation endproducts in food and their effects on health
Poulsen, M. W., Hedegaard, R. V., Andersen, J. M., de Courten, B., Bügel, S., Nielsen, J., Skibsted, L. H., & Dragsted, L. O. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.06.052 · Cited by 751 · cited 4×
“Meanwhile, serum sRAGE level was greatly influenced by food-derived AGEs [5,21,22].”
BackgroundInfluentialDeane, R., Wu, Z., & Zlokovic, B. V. (2004) · Stroke · doi:10.1161/01.str.0000143452.85382.d1 · Cited by 392
Rage and arthritis: The G82S polymorphism amplifies the inflammatory response
Hofmann, M. A., Drury, S., Hudson, B. I., Gleason, M. R., Qu, W., Lu, Y., Lalla, E., Chitnis, S., Monteiro, J., Stickland, M. H., et al. (2002) · Genes & Immunity · doi:10.1038/sj.gene.6363861 · Cited by 383 · cited 1×
“Thus, recombinant sRAGE has been successfully tested in several animal models for the treatment of RAGE-mediated diseases including type II collagen-induced arthritis [16].”
BackgroundNeuropsychiatric symptoms in the prodromal stages of dementia
Stella, F., Radanovic, M., Balthazar, M. L. F., Canineu, P. R., de Souza, L. C., & Forlenza, O. V. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000050 · Cited by 90 · cited 1×
“Patients with AD develop a gradual decline in memory and mental states as well as behavioral abilities [2].”
Background
Cited by
Twarda-Clapa, A., Olczak, A., Białkowska, A. M., & Koziołkiewicz, M. (2022) · Cells · doi:10.3390/cells11081312 · Cited by 746
Cardoso, A. L., Fernandes, A., Aguilar-Pimentel, J. A., de Angelis, M. H., Guedes, J. R., Brito, M. A., Ortolano, S., Pani, G., Athanasopoulou, S., Gonos, E. S., et al. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.004 · Cited by 475
Role of Blood-Brain Barrier in Alzheimer’s Disease
Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180098 · Cited by 370
“More notable, though, is that sRAGE, the extracellular ligand-binding decoy of RAGE, may blockade the ligand-RAGE interaction, and then suppress A (cid:2) -RAGE interaction and prevent extracellular A (cid:2) into cells or circulating A (cid:2) into brain parenchyma [67, 78, 79].”
Paudel, Y. N., Angelopoulou, E., Piperi, C., Othman, I., Aamir, K., & Shaikh, M. F. (2020) · Cells · doi:10.3390/cells9020383 · Cited by 257
Li, Y., Peng, Y., Shen, Y., Zhang, Y., Liu, L., & Yang, X. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2076064 · Cited by 156
“Noteworthy, the concentration of sRAGE in patients with neurodegenerative diseases (suffering from AD) was significantly lower than that in healthy individuals (Xu et al. 2017).”
BackgroundSelf-citation
Metadata
- Authors
- Xu, X.-Y., Deng, C.-Q., Wang, J., Deng, X.-J., Xiao, Q., Li, Y., He, Q., Fan, W.-H., Quan, F.-Y., Zhu, Y.-P., Cheng, P., & Chen, G.-J.
- Venue
- International Journal of Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2016-06-21
- Volume
- 127
- Issue
- 5
- Pages
- 454-458
- ISSN
- 0020-7454 (ISSN-L)
- 1543-5245
- OpenAlex
- W2473977470
- Cited by
- 35
- References
- 6
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma levels of soluble receptor for advanced glycation end products in Alzheimer's disease. https://app.cochat.ai/papers/10.1080/00207454.2016.1193861
- The paper
- Xu, X.-Y., Deng, C.-Q., Wang, J., Deng, X.-J., Xiao, Q., Li, Y., He, Q., Fan, W.-H., Quan, F.-Y., Zhu, Y.-P., Cheng, P., & Chen, G.-J. (2017). Plasma levels of soluble receptor for advanced glycation end products in Alzheimer's disease. International Journal of Neuroscience. https://doi.org/10.1080/00207454.2016.1193861
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.